Clinical trial
Efficacy and Physiology of Nasal High Flow Therapy (AIRVO2™, Fisher&Paykel) in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Hypercapnic Respiratory Failure
NCT02083120 is registered in ClinicalTrials.gov with Institut für Pneumologie Hagen Ambrock eV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Physiology of Nasal High Flow Therapy (AIRVO2™, Fisher&Paykel) in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Hypercapnic Respiratory Failure
- Lead sponsor
- Institut für Pneumologie Hagen Ambrock eV
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- April 30, 2014
- Completion date
- November 1, 2018
- Enrollment
- 46 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.